Literature DB >> 8675161

Liver abscess formation after local treatment of liver tumors.

T de Baère1, A Roche, J M Amenabar, C Lagrange, M Ducreux, P Rougier, D Elias, P Lasser, C Patriarche.   

Abstract

Our goal was to determine a subset of patients at high risk of developing liver abscesses after local treatment of liver tumors (LTLT) and establish guidelines for the conduct of LTLT in the safest conditions in such patients. Five hundred sixty-one LTLT, 489 transhepatic arterial chemoembolizations (TAC, 10 hepatic embolizations, and 62 percutaneous intratumor injections (PIT), were retrospectively reviewed for liver parenchyma necrosis and abscess formation. Four patients developed abscesses, three after TAC and one after PIT. Despite broad-spectrum antibiotherapy, percutaneous drainage, and surgery, two patients died. A left hepatectomy was required in the other two patients for cure. All four patients had a carcinoid or a neuroendocrine pancreatic tumor. Three out of four patients had bilioenteric anastomoses, and the fourth had recently undergone cholecystectomy and papillotomy. A Lipiodol/doxorubicin mixture without any particulate embolization was injected in the three patients who developed abscesses after TAC. LTLT in patients with bilio enteric anastomosis or papillotomy and/or neuroendocrine or carcinoid tumor should be performed with strict precautions during the procedure and for peri-procedural care.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8675161     DOI: 10.1002/hep.510230620

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  18 in total

1.  Computed Tomography-guided Drainage of Intra-abdominal Infections.

Authors:  John R. Haaga; Dean Nakamoto
Journal:  Curr Infect Dis Rep       Date:  2004-04       Impact factor: 3.725

2.  Antibiotic prophylaxis in transarterial therapy of hepatocellular carcinoma: a meta-analysis.

Authors:  Jun Wang; Xiao Dong He; You Cheng Zhang
Journal:  Can J Gastroenterol       Date:  2012-02       Impact factor: 3.522

Review 3.  Bland Liver Tumor Embolization Complicated by Hepatic Abscess.

Authors:  Omar H Elsayed-Ali; Andrew J Lipnik; Daniel B Brown
Journal:  Semin Intervent Radiol       Date:  2015-09       Impact factor: 1.513

4.  Prophylactic antibiotic guidelines in modern interventional radiology practice.

Authors:  Eunice Moon; Matthew D B S Tam; Raghid N Kikano; Karunakaravel Karuppasamy
Journal:  Semin Intervent Radiol       Date:  2010-12       Impact factor: 1.513

5.  Liver abscess following transarterial chemoembolization.

Authors:  Danny Cheng
Journal:  Semin Intervent Radiol       Date:  2011-12       Impact factor: 1.513

Review 6.  Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract.

Authors:  Magaly Zappa; Mohamed Abdel-Rehim; Olivia Hentic; Marie-Pierre Vullierme; Philippe Ruszniewski; Valérie Vilgrain
Journal:  Target Oncol       Date:  2012-05-22       Impact factor: 4.493

7.  Adverse effects of irreversible electroporation of malignant liver tumors under CT fluoroscopic guidance: a single-center experience.

Authors:  Marco Dollinger; Lukas Philipp Beyer; Michael Haimerl; Christoph Niessen; Ernst Michael Jung; Florian Zeman; Christian Stroszczynski; Philipp Wiggermann
Journal:  Diagn Interv Radiol       Date:  2015 Nov-Dec       Impact factor: 2.630

Review 8.  [Arterial embolization of hepatic metastases from neuroendocrine tumors].

Authors:  M Libicher; H Bovenschulte
Journal:  Radiologe       Date:  2009-03       Impact factor: 0.635

9.  Learning curve for radiofrequency ablation of liver tumors: prospective analysis of initial 100 patients in a tertiary institution.

Authors:  Ronnie T Poon; Kelvin K Ng; Chi Ming Lam; Victor Ai; Jimmy Yuen; Sheung Tat Fan; John Wong
Journal:  Ann Surg       Date:  2004-04       Impact factor: 12.969

Review 10.  Liver transarterial embolizations in metastatic neuroendocrine tumors.

Authors:  Louis de Mestier; Magaly Zappa; Olivia Hentic; Valérie Vilgrain; Philippe Ruszniewski
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.